J. A. Burger Et Al. , "Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies," LEUKEMIA & LYMPHOMA , vol.63, no.6, pp.1375-1386, 2022
Burger, J. A. Et Al. 2022. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. LEUKEMIA & LYMPHOMA , vol.63, no.6 , 1375-1386.
Burger, J. A., Robak, T., DEMİRKAN, F., Bairey, O., Moreno, C., Simpson, D., ... Munir, T.(2022). Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. LEUKEMIA & LYMPHOMA , vol.63, no.6, 1375-1386.
Burger, Jan Et Al. "Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies," LEUKEMIA & LYMPHOMA , vol.63, no.6, 1375-1386, 2022
Burger, Jan A. Et Al. "Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies." LEUKEMIA & LYMPHOMA , vol.63, no.6, pp.1375-1386, 2022
Burger, J. A. Et Al. (2022) . "Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies." LEUKEMIA & LYMPHOMA , vol.63, no.6, pp.1375-1386.
@article{article, author={Jan A. Burger Et Al. }, title={Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies}, journal={LEUKEMIA & LYMPHOMA}, year=2022, pages={1375-1386} }